n> and
January 27, 2010. This press release does
not constitute an offer to sell, or the solicitation of an offer to buy,
securities, and does not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be unlawful.
Copies of the prospectus supplement and the accompanying prospectus relating
to this offering may be obtained from UBS Securities LLC, Attention:
Prospectus Department, 299 Park Avenue,
New York, NY 10171,
U.S.A., telephone:
888-827-7275, or
Piper Jaffray & Co., Attention: Equity Capital Markets, 800
Nicollet Mall, Suite 800,
Minneapolis MN 55402,
U.S.A., telephone:
1-800-754-4781.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against infectious diseases. Sinovac's vaccine products
include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and
Anflu(R) (influenza). Panflu(R) and Panflu.1(TM), Sinovac's pandemic influenza
vaccine (H5N1) and H1N1 vaccine, have already been approved for government
stockpiling. Sinovac is developing vaccines for a number of different
infectious diseases including enterovirus 71, pneumococcal disease, Japanese
encephalitis, haemophilus influenzae type b (Hib), meningitis, rabies,
chickenpox, mumps and rubella. Sinovac is also conducting field trials for
independently developed inactivated animal rabies vaccine.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning
of the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. All statements other than statements
'/>"/>
SOURCE Sinovac Biotech Ltd. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Sinovac Announces Postponement of Annual General Meeting2.
Sinovac Requests Extension for Annual Shareholders Meeting3.
Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine4.
Sinovac Closes $9.75 Million Private Placement5.
Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders6.
Sinovac Announces Adjournment of Annual General Meeting7.
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results8.
Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results9.
Sinovac Biotech Holds Annual General Meeting10.
Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 200811.
Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims